Loading…
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
69pct
10d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2024 · fourth_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medical/Disease Research/Clinical Labs
Issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, Issues related to medical adoption of psychedelic drugs and therapies, Issues related to equitable access to psychedelic drugs and therapies, Issues related to a pathway for FDA approval of psychedelic drugs and therapies, S. 689/H.R. 1393, a bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, Issues related to medical adoption of psychedelic drugs and therapies, Issues related to equitable access to psychedelic drugs and therapies, Issues related to a pathway for FDA approval of psychedelic drugs and therapies, S. 689/H.R. 1393, a bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medical/Disease Research/Clinical Labs
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general.
Client expense: Not reported · Firm income: Not reported
2024 · first_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $20,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Insurance
H.R. 900 Flood Insurance Coverage Requirements; HR 1393 National Flood Insurance Extension Act; and issues related to the oversight of the National Flood Insurance Program; HR 5860 Continuation of funding of the National Flood Insurance Program and Issues related to lender-placed insurance
Client expense: $140,000 · Firm income: Not reported
Government targets: Consumer Financial Protection Bureau (CFPB), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Veterans
Lobbied to garner support and cosponsors on H.R. 1393 and S.5132, The Breakthrough Therapies Act
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Insurance
H.R. 900 Flood Insurance Coverage Requirements; HR 1393 National Flood Insurance Extension Act; and issues related to the oversight of the National Flood Insurance Program
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2023 · second_quarter · Insurance
H.R. 900 Flood Insurance Coverage Requirements; HR 1393 National Flood Insurance Extension Act; and issues related to the oversight of the National Flood Insurance Program
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2023 · second_quarter · Health Issues
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general
Client expense: Not reported · Firm income: Not reported
2023 · first_quarter · Insurance
H.R. 900 (Flood Insurance Coverage Requirements),and HR 1393 (National Flood Insurance Extension Act)
Client expense: $360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
| Democratic |
| TX |
| Derrick Van Orden | Republican | WI |
| Don Bacon | Republican | NE |
| Earl Blumenauer | Democratic | OR |
| James R. Baird | Republican | IN |
| Jasmine Crockett | Democratic | TX |
| Mariannette Miller-Meeks | Republican | IA |
| Mike Thompson | Democratic | CA |
| Morgan Luttrell | Republican | TX |
| Nancy Mace | Republican | SC |
| Ro Khanna | Democratic | CA |
| Robert Garcia | Democratic | CA |
| Sheila Jackson Lee | Democratic | TX |
| Ted Lieu | Democratic | CA |
| Zachary Nunn | Republican | IA |